PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Human cytomegalovirus in high grade serous ovarian cancer possible implications for patients survival.

Abstract Patients diagnosed with high grade serous ovarian adenocarcinoma have a poor prognosis. Recently human cytomegalovirus (HCMV) has been detected in several tumors. Here, we evaluated HCMV in ovarian cancer tissue specimens obtained at pre- and postchemotherapy tumor resection.Available paraffin embedded ovarian cancer tissues from matched pre- and postchemotherapy tumor resection specimens (i.e., diagnostic excisional biopsy prechemotherapy; DEBPC) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT + IDS) from 10 patients with stage IIIC-IV high grade serous ovarian carcinoma (HGS) diagnosed between years 2007 and 2008 at Karolinska University Hospital were examined for HCMV immediate-early protein (HCMV-IE), tegument protein pp65, and nucleic acid (β2.7) by immunohistochemistry and in situ hybridization.HCMV-IE and pp65 were detected in 8/10 (80%), 4/9 (44%) and in 4/10 (40%), 5/8 in ovarian cancer tissue specimens from DEBPC and NACT + IDS, respectively. HCMV-β2.7 was detected in all available tissue sections obtained from DEBPC and NACT + IDS. Patients with HCMV-IE or pp65 positive cells in their ovarian tumors at IDS after NACT had a median overall survival of 23.4 and 18.2 months, respectively, compared to 29.6 and 54 months, respectively, in those who did not express HCMV proteins in their tumors.In conclusion, HCMV proteins and nucleic acids are frequently detected at different levels in HGS ovarian carcinoma. Despite the limitation of our study, shorter median overall survival of patients with HCMV-IE and pp65 in their tumor highlights the need to further investigate the role of HCMV in ovarian cancer patients.
PMID
Related Publications

Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.

The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.

Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.

Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.

Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29369188
OWN - NLM
STAT- In-Process
LR  - 20180125
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 4
DP  - 2018 Jan
TI  - Human cytomegalovirus in high grade serous ovarian cancer possible implications
      for patients survival.
PG  - e9685
LID - 10.1097/MD.0000000000009685 [doi]
AB  - Patients diagnosed with high grade serous ovarian adenocarcinoma have a poor
      prognosis. Recently human cytomegalovirus (HCMV) has been detected in several
      tumors. Here, we evaluated HCMV in ovarian cancer tissue specimens obtained at
      pre- and postchemotherapy tumor resection.Available paraffin embedded ovarian
      cancer tissues from matched pre- and postchemotherapy tumor resection specimens
      (i.e., diagnostic excisional biopsy prechemotherapy; DEBPC) and neoadjuvant
      chemotherapy followed by interval debulking surgery (NACT + IDS) from 10 patients
      with stage IIIC-IV high grade serous ovarian carcinoma (HGS) diagnosed between
      years 2007 and 2008 at Karolinska University Hospital were examined for HCMV
      immediate-early protein (HCMV-IE), tegument protein pp65, and nucleic acid
      (beta2.7) by immunohistochemistry and in situ hybridization.HCMV-IE and pp65 were
      detected in 8/10 (80%), 4/9 (44%) and in 4/10 (40%), 5/8 in ovarian cancer tissue
      specimens from DEBPC and NACT + IDS, respectively. HCMV-beta2.7 was detected in
      all available tissue sections obtained from DEBPC and NACT + IDS. Patients with
      HCMV-IE or pp65 positive cells in their ovarian tumors at IDS after NACT had a
      median overall survival of 23.4 and 18.2 months, respectively, compared to 29.6
      and 54 months, respectively, in those who did not express HCMV proteins in their 
      tumors.In conclusion, HCMV proteins and nucleic acids are frequently detected at 
      different levels in HGS ovarian carcinoma. Despite the limitation of our study,
      shorter median overall survival of patients with HCMV-IE and pp65 in their tumor 
      highlights the need to further investigate the role of HCMV in ovarian cancer
      patients.
FAU - Carlson, Joseph W
AU  - Carlson JW
AD  - Department of Pathology and Cytology, Institute for Oncology-Pathology.
FAU - Radestad, Angelique Floter
AU  - Radestad AF
AD  - Department of Women's and Children's Health, Karolinska Institutet and Division
      of Obstetrics and Gynecology, Karolinska University Hospital.
FAU - Soderberg-Naucler, Cecilia
AU  - Soderberg-Naucler C
AD  - Department of Medicine Solna, Unit of Microbial Pathogenesis and Department of
      Neurology, Centre for Molecular Medicine, Karolinska Institutet, Stockholm,
      Sweden.
FAU - Rahbar, Afsar
AU  - Rahbar A
AD  - Department of Medicine Solna, Unit of Microbial Pathogenesis and Department of
      Neurology, Centre for Molecular Medicine, Karolinska Institutet, Stockholm,
      Sweden.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
EDAT- 2018/01/26 06:00
MHDA- 2018/01/26 06:00
CRDT- 2018/01/26 06:00
PHST- 2018/01/26 06:00 [entrez]
PHST- 2018/01/26 06:00 [pubmed]
PHST- 2018/01/26 06:00 [medline]
AID - 10.1097/MD.0000000000009685 [doi]
AID - 00005792-201801260-00021 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Jan;97(4):e9685. doi: 10.1097/MD.0000000000009685.